--- title: "Atossa Therapeutics (ATOS) news: reverse split and offering" url: "https://aibio.space/companies/atossa-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ATOS reverse split, offering and Nasdaq notice news: Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule. Atossa Therapeutics, Inc." --- ATOS Atossa Therapeutics, Inc. NASDAQ · United States # Atossa Therapeutics (ATOS) news ATOS reverse split, offering and Nasdaq notice news Listings · 2026-02-17 ## [Atossa Therapeutics regains Nasdaq minimum bid price compliance](https://aibio.space/news/atossa-therapeutics-regains-nasdaq-minimum-bid-price-compliance/) Atossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025. ## Latest Atossa Therapeutics news 1. 2025-08-21 Listings [Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule](https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/) The new deadline is February 17, 2026. Atossa said it may consider a reverse stock split if needed. 2. 2025-02-24 Listings [Atossa Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 20, 2025](https://aibio.space/news/atossa-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/) Nasdaq says the stock closed below $1.00 for 30 consecutive business days. The company has until August 20, 2025 to cure, and a second 180-day period is possible. 3. 2024-11-19 Financings [Atossa Therapeutics sets up $100,000,000 at-the-market stock program with Jefferies](https://aibio.space/news/atossa-therapeutics-sets-up-100-000-000-market-stock-program-jefferies/) Jefferies will earn a commission of up to 3.0% on any shares sold. The stock last sold at $1.28 on November 15, 2024. ## Atossa Therapeutics at a glance - **Ticker**: ATOS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $26.1 million ### Related companies - [Johnson & Johnson](https://aibio.space/companies/johnson-johnson/) NYSE: JNJ - [KALA BIO](https://aibio.space/companies/kala-bio/) NASDAQ: KALA - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) NASDAQ: SIGA - [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) NASDAQ: AVLN - [Trevena](https://aibio.space/companies/trevena/) OTC: TRVN - [Vaxxinity](https://aibio.space/companies/vaxxinity/) OTC: VAXX - [Collegium Pharmaceutical](https://aibio.space/companies/collegium-pharmaceutical/) NASDAQ: COLL - [REGENXBIO](https://aibio.space/companies/regenxbio/) NASDAQ: RGNX ### Also on NASDAQ - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) ELDN - [Xenon Pharmaceuticals](https://aibio.space/companies/xenon-pharmaceuticals/) XENE - [Lifevantage](https://aibio.space/companies/lifevantage/) LFVN - [Genprex](https://aibio.space/companies/genprex/) GNPX - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) SNDX - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) BCYC ## What Atossa Therapeutics does Atossa Therapeutics is a company whose lead program is (Z)-endoxifen, a proprietary active metabolite of tamoxifen. Its forward-looking statements describe clinical trials of (Z)-endoxifen in women with breast cancer and its ability to pursue a Duchenne muscular dystrophy (DMD) indication for the same molecule. The company says it is seeking an accelerated path to filing a New Drug Application with the U.S. Food and Drug Administration, which depends on the timing of FDA submissions and interactions. It also says it may be eligible for the Rare Pediatric Disease Priority Review Voucher program and for orphan-drug exclusivity for (Z)-endoxifen in DMD. The report lists the ability to continue as a going concern among its forward-looking statements, along with its ability to contract with third-party suppliers, manufacturers and clinical research organizations. The company also refers to efforts to deploy artificial intelligence in its own or its collaborators' product candidates, and it lists its common stock on the Nasdaq Capital Market. | Product or program | What it is | Stage | |---|---|---| | (Z)-endoxifen | Proprietary active metabolite of tamoxifen; lead program, with breast cancer and DMD indications | Clinical trials in women with breast cancer planned or ongoing; DMD indication being pursued | Summarised from the company's [10-K filed Mar 25, 2026](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/atos-20251231.htm). ## Atossa Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$21.2 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | [$14.1 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | | Net income (loss) | [-$34.8 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | [-$25.5 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | | Cash from operations | [-$29.8 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | [-$21.0 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | | Cash and equivalents | [$41.3 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526339257/) | [$71.1 million](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Negative view 2026-10-28 [Atossa has about nine months of cash, and we expect another raise within the year](https://aibio.space/analysis/atossa-has-about-nine-months-cash-we-expect-another-raise/) The filings say existing resources will likely not cover the next twelve months. The early drug data are small, and they do not solve the money problem. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Atossa Therapeutics Did Atossa Therapeutics do a reverse stock split? Our latest story on this, dated Aug 21, 2025: "Atossa Therapeutics gets 180 more days to meet Nasdaq $1.00 bid price rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atossa-therapeutics-gets-180-more-days-meet-nasdaq-1-00-bid-price-rule/). Has Atossa Therapeutics raised money recently? Our latest story on this, dated Nov 19, 2024: "Atossa Therapeutics sets up $100,000,000 at-the-market stock program with Jefferies". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atossa-therapeutics-sets-up-100-000-000-market-stock-program-jefferies/). Has Atossa Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Feb 24, 2025: "Atossa Therapeutics gets Nasdaq minimum bid price deficiency notice, has until August 20, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/atossa-therapeutics-gets-nasdaq-minimum-bid-price-deficiency-notice/). What is the ticker symbol of Atossa Therapeutics? Atossa Therapeutics, Inc. trades under the ticker ATOS on NASDAQ. Where is Atossa Therapeutics listed? Atossa Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BIVA:ATOS; BMV:ATOS; GETTEX:YAG. What is the SEC CIK of Atossa Therapeutics? The SEC Central Index Key (CIK) for Atossa Therapeutics, Inc. is 1488039. Its filings are on SEC EDGAR. How many shares does Atossa Therapeutics have outstanding? 9,979,298 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Atossa Therapeutics listed under? Our directory records Atossa Therapeutics, Inc. under United States. What does Atossa Therapeutics do? Our directory classifies Atossa Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Atossa Therapeutics? The ISIN recorded for Atossa Therapeutics, Inc. is US04962H7044. Does aibio.space cover Atossa Therapeutics? aibio.space lists Atossa Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Atossa Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Atossa Therapeutics develop? Atossa Therapeutics is a company whose lead program is (Z)-endoxifen, a proprietary active metabolite of tamoxifen. Its forward-looking statements describe clinical trials of (Z)-endoxifen in women with breast cancer and its ability to pursue a Duchenne muscular dystrophy (DMD) indication for the same molecule. What is (Z)-endoxifen from Atossa Therapeutics? (Z)-endoxifen: Proprietary active metabolite of tamoxifen; lead program, with breast cancer and DMD indications Stage: Clinical trials in women with breast cancer planned or ongoing; DMD indication being pursued. Is Atossa Therapeutics profitable? Atossa Therapeutics, Inc. reported a net loss of $34.8 million for the fiscal year ended Dec 31, 2025, and used $29.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Atossa Therapeutics Members talk about Atossa Therapeutics (ATOS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Atossa Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-18 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/atos-ex99_1.htm) 2. 2026-06-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/atos-20260610.htm) 3. 2026-05-08 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526213373/atos-20260507.htm) 4. 2026-03-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526131807/atos-20260330.htm) 5. 2026-03-25 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526124396/atos-20251231.htm) 6. 2026-03-20 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526117826/atos-20260320.htm) 7. 2026-02-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526061388/d89574d424b5.htm) 8. 2026-02-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526054797/atos-20260217.htm) 9. 2026-01-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312526021727/atos-20260120.htm) 10. 2025-12-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312525327630/atos-20251219.htm) 11. 2025-12-12 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000119312525317731/atos-20251212.htm) 12. 2025-08-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm) 13. 2025-02-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1488039/000095017025025596/atos-20250221.htm) 14. 2024-11-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1488039/000095017024128656/project_apex_-_424b5_atm.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ATOS on TradingView](https://www.tradingview.com/symbols/NASDAQ-ATOS/). ## SEC filings and registration - **SEC name**: Atossa Therapeutics, Inc. - **CIK**: 1488039 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ATOS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1448 NW MARKET STREET, SEATTLE, WA, 98107 - **Phone**: 206.588.0256 - **Shares outstanding**: 9,979,298 as of 2026-07-31 (10-Q filed 2026-08-07) - **Former names**: ATOSSA GENETICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1488039/000119312526418560/atos-20261008.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1488039/000119312526406036/atos-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1488039/000119312526395694/atos-20260918.htm) filed 2026-09-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1488039/000119312526339292/atos-20260807.htm) filed 2026-08-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1488039/000119312526339257/atos-20260630.htm) filed 2026-08-07 - [424B5](https://www.sec.gov/Archives/edgar/data/1488039/000119312526268597/project_rdo_june_2026_-_.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1488039/000119312526266717/atos-20260610.htm) filed 2026-06-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/atos-20260508.htm) filed 2026-05-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001488039), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Atossa Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ATOS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Atossa Therapeutics, Inc. - **Ticker**: ATOS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US04962H7044 - **Other listed symbols**: BIVA:ATOS; BMV:ATOS; GETTEX:YAG - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ATOS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/atossa-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Atossa Therapeutics (ATOS) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/atossa-therapeutics/